Calidi Biotherapeutics Unveils Data on In Situ T-Cell Engagers at AACR 2026
Event summary
- Calidi Biotherapeutics presented new data at the AACR annual meeting on April 19, 2026, showcasing its RedTail platform's ability to express T-cell engagers and IL-15 superagonist in the tumor microenvironment.
- CLD-401, the lead candidate, is expected to file an IND by the end of 2026, targeting non-small cell lung cancer and head and neck cancer.
- The company introduced CLD-501, a new candidate targeting TROP-2, addressing challenges of off-tumor toxicity with its tumor-restricted approach.
- Calidi is pursuing additional T-cell engager targets like EGFR, EpCAM, and Nectin-4.
The big picture
Calidi Biotherapeutics is addressing a critical gap in immuno-oncology: the effective delivery of T-cell engagers to solid tumors. By leveraging its RedTail platform to remodel the tumor microenvironment and confine expression of T-cell engagers to the tumor site, Calidi aims to overcome historical limitations of these therapies. The company's approach could potentially unlock new treatment options for solid tumors, a significant unmet medical need in oncology.
What we're watching
- Clinical Progress
- Whether Calidi can successfully file an IND for CLD-401 by the end of 2026 and advance its clinical trials.
- Strategic Partnerships
- The pace at which Calidi secures partnerships to accelerate the development of its RedTail platform.
- Market Differentiation
- How Calidi's tumor-restricted approach to T-cell engagers will position it against competitors in the immuno-oncology space.
Related topics